FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200014243> ?p ?o ?g. }

• W4200014243 endingPage "639" @default.
• W4200014243 startingPage "629" @default.
• W4200014243 abstract "Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell therapy approved for diffuse large B-cell lymphoma after at least two treatment lines.We conducted an international phase 3 trial involving patients with aggressive lymphoma that was refractory to or progressing within 12 months after first-line therapy. Patients were randomly assigned to receive tisagenlecleucel with optional bridging therapy (tisagenlecleucel group) or salvage chemotherapy and autologous hematopoietic stem-cell transplantation (HSCT) (standard-care group). The primary end point was event-free survival, defined as the time from randomization to stable or progressive disease at or after the week 12 assessment or death. Crossover to receive tisagenlecleucel was allowed if a defined event occurred at or after the week 12 assessment. Other end points included response and safety.A total of 322 patients underwent randomization. At baseline, the percentage of patients with high-grade lymphomas was higher in the tisagenlecleucel group than in the standard-care group (24.1% vs. 16.9%), as was the percentage with an International Prognostic Index score (range, 0 to 5, with higher scores indicating a worse prognosis) of 2 or higher (65.4% vs. 57.5%). A total of 95.7% of the patients in the tisagenlecleucel group received tisagenlecleucel; 32.5% of the patients in the standard-care group received autologous HSCT. The median time from leukapheresis to tisagenlecleucel infusion was 52 days. A total of 25.9% of the patients in the tisagenlecleucel group had lymphoma progression at week 6, as compared with 13.8% of those in the standard-care group. The median event-free survival in both groups was 3.0 months (hazard ratio for event or death in the tisagenlecleucel group, 1.07; 95% confidence interval, 0.82 to 1.40; P = 0.61). A response occurred in 46.3% of the patients in the tisagenlecleucel group and in 42.5% in the standard-care group. Ten patients in the tisagenlecleucel group and 13 in the standard-care group died from adverse events.Tisagenlecleucel was not superior to standard salvage therapy in this trial. Additional studies are needed to assess which patients may obtain the most benefit from each approach. (Funded by Novartis; BELINDA ClinicalTrials.gov number, NCT03570892.)." @default.
• W4200014243 created "2021-12-31" @default.
• W4200014243 creator A5000959540 @default.
• W4200014243 creator A5002394921 @default.
• W4200014243 creator A5013424590 @default.
• W4200014243 creator A5016122215 @default.
• W4200014243 creator A5016370299 @default.
• W4200014243 creator A5016952242 @default.
• W4200014243 creator A5017327825 @default.
• W4200014243 creator A5021496101 @default.
• W4200014243 creator A5025125007 @default.
• W4200014243 creator A5027391845 @default.
• W4200014243 creator A5028164155 @default.
• W4200014243 creator A5033073385 @default.
• W4200014243 creator A5034182883 @default.
• W4200014243 creator A5034222353 @default.
• W4200014243 creator A5036293139 @default.
• W4200014243 creator A5039994927 @default.
• W4200014243 creator A5040138933 @default.
• W4200014243 creator A5046049357 @default.
• W4200014243 creator A5049413660 @default.
• W4200014243 creator A5050448276 @default.
• W4200014243 creator A5051605599 @default.
• W4200014243 creator A5051862003 @default.
• W4200014243 creator A5052064208 @default.
• W4200014243 creator A5052942241 @default.
• W4200014243 creator A5053019069 @default.
• W4200014243 creator A5058187626 @default.
• W4200014243 creator A5062669259 @default.
• W4200014243 creator A5062810471 @default.
• W4200014243 creator A5064132655 @default.
• W4200014243 creator A5065110305 @default.
• W4200014243 creator A5068715900 @default.
• W4200014243 creator A5077430940 @default.
• W4200014243 creator A5078460534 @default.
• W4200014243 creator A5080630441 @default.
• W4200014243 creator A5081234421 @default.
• W4200014243 creator A5081301408 @default.
• W4200014243 creator A5081343057 @default.
• W4200014243 creator A5082045927 @default.
• W4200014243 creator A5082092102 @default.
• W4200014243 creator A5088720489 @default.
• W4200014243 creator A5089893290 @default.
• W4200014243 date "2022-02-17" @default.
• W4200014243 modified "2023-10-18" @default.
• W4200014243 title "Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma" @default.
• W4200014243 cites W2119147717 @default.
• W4200014243 cites W2133345449 @default.
• W4200014243 cites W2305142474 @default.
• W4200014243 cites W2556342759 @default.
• W4200014243 cites W2565561569 @default.
• W4200014243 cites W2787301955 @default.
• W4200014243 cites W2903062212 @default.
• W4200014243 cites W3012524939 @default.
• W4200014243 cites W3016273290 @default.
• W4200014243 cites W3024978145 @default.
• W4200014243 cites W3037170173 @default.
• W4200014243 cites W3037322433 @default.
• W4200014243 cites W3043369050 @default.
• W4200014243 cites W3092023747 @default.
• W4200014243 cites W3134205746 @default.
• W4200014243 cites W3201013983 @default.
• W4200014243 doi "https://doi.org/10.1056/nejmoa2116596" @default.
• W4200014243 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34904798" @default.
• W4200014243 hasPublicationYear "2022" @default.
• W4200014243 type Work @default.
• W4200014243 citedByCount "186" @default.
• W4200014243 countsByYear W42000142432022 @default.
• W4200014243 countsByYear W42000142432023 @default.
• W4200014243 crossrefType "journal-article" @default.
• W4200014243 hasAuthorship W4200014243A5000959540 @default.
• W4200014243 hasAuthorship W4200014243A5002394921 @default.
• W4200014243 hasAuthorship W4200014243A5013424590 @default.
• W4200014243 hasAuthorship W4200014243A5016122215 @default.
• W4200014243 hasAuthorship W4200014243A5016370299 @default.
• W4200014243 hasAuthorship W4200014243A5016952242 @default.
• W4200014243 hasAuthorship W4200014243A5017327825 @default.
• W4200014243 hasAuthorship W4200014243A5021496101 @default.
• W4200014243 hasAuthorship W4200014243A5025125007 @default.
• W4200014243 hasAuthorship W4200014243A5027391845 @default.
• W4200014243 hasAuthorship W4200014243A5028164155 @default.
• W4200014243 hasAuthorship W4200014243A5033073385 @default.
• W4200014243 hasAuthorship W4200014243A5034182883 @default.
• W4200014243 hasAuthorship W4200014243A5034222353 @default.
• W4200014243 hasAuthorship W4200014243A5036293139 @default.
• W4200014243 hasAuthorship W4200014243A5039994927 @default.
• W4200014243 hasAuthorship W4200014243A5040138933 @default.
• W4200014243 hasAuthorship W4200014243A5046049357 @default.
• W4200014243 hasAuthorship W4200014243A5049413660 @default.
• W4200014243 hasAuthorship W4200014243A5050448276 @default.
• W4200014243 hasAuthorship W4200014243A5051605599 @default.
• W4200014243 hasAuthorship W4200014243A5051862003 @default.
• W4200014243 hasAuthorship W4200014243A5052064208 @default.
• W4200014243 hasAuthorship W4200014243A5052942241 @default.
• W4200014243 hasAuthorship W4200014243A5053019069 @default.
• W4200014243 hasAuthorship W4200014243A5058187626 @default.
• W4200014243 hasAuthorship W4200014243A5062669259 @default.
• W4200014243 hasAuthorship W4200014243A5062810471 @default.

• next